GLSI — Greenwich Lifesciences Income Statement
0.000.00%
Last trade - 00:00
- $191.01m
- $185.50m
- 43
- 13
- 74
- 39
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 3.43 | 1.86 | 4.6 | 8.04 | 9.33 |
Operating Profit | -3.43 | -1.86 | -4.6 | -8.04 | -9.33 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -3.43 | -1.86 | -4.57 | -7.83 | -8.89 |
Net Income After Taxes | -3.43 | -1.86 | -4.57 | -7.83 | -8.89 |
Net Income Before Extraordinary Items | |||||
Net Income | -3.43 | -1.86 | -4.57 | -7.83 | -8.89 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -3.43 | -1.86 | -4.57 | -7.83 | -8.89 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.286 | -0.147 | -0.353 | -0.606 | -0.692 |
Dividends per Share |